Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment
Related Experiment Video
Updated: May 17, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
Published on: April 1, 2015
R van der Pas1, F W G Leebeek, L J Hofland
1Department of Internal Medicine, Division of Endocrinology, Erasmus MC, Rotterdam, The Netherlands. r.vanderpas@erasmusmc.nl
Insights
Patients with Cushing's syndrome (CS) face a significantly higher risk of blood clots due to a hypercoagulable state. Effective treatment and sustained remission are crucial for resolving these risks.
Area of Science:
- Endocrinology
- Hematology
- Cardiovascular Medicine
Background:
- Cushing's syndrome (CS) is associated with increased cardiovascular disease and a hypercoagulable state.
- Patients with CS exhibit a markedly elevated risk (over 10-fold) of venous thromboembolism (VTE).
- Postoperative thrombosis risk in CS patients mirrors that of major orthopedic surgery.
Purpose of the Study:
- To elucidate the mechanisms underlying hypercoagulability in Cushing's syndrome.
- To assess the impact of surgical intervention on the hypercoagulable state.
- To evaluate the potential need for thromboprophylaxis in active CS.
Main Methods:
- Analysis of coagulation parameters in patients with Cushing's syndrome.
- Evaluation of fibrinolytic capacity and clotting times.
- Assessment of changes in hypercoagulability markers post-surgery.
Main Results:
- Hypercoagulability in CS results from increased procoagulant factor production and impaired fibrinolysis.
- Activated partial thromboplastin time is shortened, and clot lysis time is increased in CS patients.
- These hemostatic abnormalities partially improve one year post-surgery but do not normalize.
Conclusions:
- Sustained biochemical remission may be necessary to fully resolve the hypercoagulable state in CS.
- Thromboprophylaxis is potentially warranted for active CS patients, particularly perioperatively.
- Further research is required to establish optimal thromboprophylaxis strategies for CS.
Abstract:
Cushing's syndrome is not only accompanied by an increased prevalence of cardiovascular disease but also by a hypercoagulable state that is reflected by an increased incidence of venous thromboembolism. Overall, patients with CS have been reported to have a more than 10-fold increased risk of developing venous thromboembolism. Moreover, the incidence of postoperative thrombosis has been shown to be comparable to the risk after major orthopaedic surgery. Hypercoagulability in CS is due to both increased production of procoagulant factors with activation of the coagulation cascade and an impaired fibrinolytic capacity, resulting in a shortened activated partial thromboplastin time and an increased clot lysis time respectively. Although these abnormalities seem to improve 1 year following successful surgery, they do not yet normalize. Therefore, sustained biochemical remission might be required to fully resolve the hypercoagulable state in CS. Considering the risk of venous thromboembolism in uncontrolled CS there may be a rationale to give patients with active CS thromboprophylaxis. So far this seems warranted following surgical interventions. However, further studies are needed to determine the optimal dosage and duration of thromboprophylaxis.
Related Concept Videos
Cushing Syndrome I: Introduction
Cushing Syndrome II: Pathophysiology
Adrenal Gland Disorders
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
